AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17479824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 298
Study 15281492 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 unit of allogeneic RBCs (transfusion 1; n = 17)
Number of subjects: 51
Study 15281492 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 units of allogeneic RBCs (transfusion 2; n = 17)
Number of subjects: 51
Study 15281492 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen ventilation (n = 17)
Number of subjects: 51
Study 11340315 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot Reflex Zone Massage (FRZM) therapy
Number of subjects: 32
Study 11340315 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (massage on zones unrelated to the intestines)
Number of subjects: 32
Study 9389899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (100 mg dl-alpha-tocopheryl acetate daily for 3 months)
Number of subjects: 74
Study 9389899 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation
Number of subjects: 74
Study 9389899 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 74
Study 8184351 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS/CODETRON) with exercise regimen
Number of subjects: 58
Study 8184351 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation with exercise regimen
Number of subjects: 58
Study 8184351 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 58
Study 3115833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous leuprolide (500 micrograms/day)
Number of subjects: 14
Study 3115833 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal leuprolide (1600 micrograms/day)
Number of subjects: 14
Study 28964904 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported hunger
Number of subjects: 32
Study 28964904 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported thirst
Number of subjects: 32
Study 28964904 — intervention group
Group type: EXPERIMENTAL
Intervention: Other constructs (hunger, fullness, emptiness, appetite)
Number of subjects: 32
Study 28964904 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariates in fMRI models
Number of subjects: 32
Study 28964904 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective self-reported hunger, satiety and related constructs
Number of subjects: 32
Study 27706483 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg, once daily, for 14 days)
Number of subjects: 260
Study 27706483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 27706483 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 260
Study 25569053 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous suture
Number of subjects: 180
Study 25569053 — intervention group
Group type: COMPARATOR
Intervention: Control (no subcutaneous suture)
Number of subjects: 180
Study 23678038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17β-estradiol (E₂) at a mean dose of 2 mg
Number of subjects: 40
Study 23678038 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17β-estradiol (E₂) at a mean dose of 0.1 mg
Number of subjects: 40
Study 20519423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 mL (50 microg) added to local anesthetics
Number of subjects: 77
Study 20519423 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo 1 mL
Number of subjects: 77
Study 17983881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulky dressing removed at 24 hours
Number of subjects: 100
Study 17983881 — intervention group
Group type: COMPARATOR
Intervention: Bulky dressing removed at 2 weeks
Number of subjects: 100
Study 16365322 — intervention group
Group type: EXPERIMENTAL
Intervention: True intervention group (n = 18)
Number of subjects: 38
Study 16365322 — intervention group
Group type: COMPARATOR
Intervention: Sham control group (n = 20)
Number of subjects: 38
Study 14669194 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency vibration training (28Hz) for three 2-minute sessions, twice weekly for 6 months
Number of subjects: 29
Study 14669194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 29
Study 14669194 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency vibration training (28Hz)
Number of subjects: 29
Study 10974208 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP‐choline (citicoline; 500 mg)
Number of subjects: 12
Study 10974208 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP‐choline (citicoline; 2000 mg)
Number of subjects: 12
Study 10974208 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP‐choline (citicoline; 4000 mg)
Number of subjects: 12
Study 10974208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9058178 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (N = 8)
Number of subjects: 16
Study 9058178 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 8)
Number of subjects: 16
Study 8396833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 6 mg
Number of subjects: 134
Study 8396833 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan 12 mg
Number of subjects: 134
Study 8396833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 3520601 — intervention group
Group type: COMPARATOR
Intervention: 200 mg clotrimazole vaginal tablets once daily for 3 consecutive days
Number of subjects: 60
Study 3520601 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg terconazole vaginal tablets once daily for 3 consecutive days
Number of subjects: 60
Study 3520601 — intervention group
Group type: EXPERIMENTAL
Intervention: one 240 mg terconazole vaginal tablet followed by 2 identical placebo pessaries
Number of subjects: 60
Study 30927498 — intervention group
Group type: EXPERIMENTAL
Intervention: CXP (novel resorbable non‐cross‐linked collagen membrane)
Number of subjects: 49
Study 30927498 — intervention group
Group type: COMPARATOR
Intervention: BG (non‐cross‐linked resorbable membrane)
Number of subjects: 49
Study 30927498 — intervention group
Group type: EXPERIMENTAL
Intervention: CXP
Number of subjects: 49
Study 30927498 — intervention group
Group type: COMPARATOR
Intervention: BG
Number of subjects: 49
Study 30927498 — intervention group
Group type: EXPERIMENTAL
Intervention: CXP and BG
Number of subjects: 49
Study 28387895 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/die)
Number of subjects: 56
Study 28387895 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 56
Study 25940902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous TPMT*1/*3A
Number of subjects: 2387
Study 25940902 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous wild-type TPMT*1/*1
Number of subjects: 2387
Study 25940902 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous TPMT*1/*3C
Number of subjects: 2387
Study 25940902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk MRD patients
Number of subjects: 2387
Study 23704994 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (25-50 mg)
Number of subjects: 54
Study 23704994 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 54
Study 23704994 — intervention group
Group type: COMPARATOR
Intervention: Standard medication (control)
Number of subjects: 54
Study 22470245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg Ondansetron
Number of subjects: 136
Study 22470245 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg Ondansetron
Number of subjects: 136
Study 22470245 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg Ondansetron
Number of subjects: 136
Study 22470245 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg and 8 mg Ondansetron
Number of subjects: 136
Study 22470245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 19321717 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills group intervention program (8 sessions, 2 hours each)
Number of subjects: 32
Study 17286787 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 20 mg with light food
Number of subjects: 21
Study 17286787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg with light food
Number of subjects: 21
Study 17286787 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg with light food
Number of subjects: 21
Study 15128344 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (omeprazole 20 mg or esomeprazole 40 mg daily)
Number of subjects: 72
Study 15128344 — intervention group
Group type: COMPARATOR
Intervention: Antacid (aluminum hydroxide 800 mg daily)
Number of subjects: 72
Study 11435263 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 37.5 mg/day
Number of subjects: 541
Study 11435263 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75 mg/day
Number of subjects: 541
Study 11435263 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 150 mg/day
Number of subjects: 541
Study 11435263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study 9728580 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent gemcitabine
Number of subjects: 0
Study 9728580 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/etoposide
Number of subjects: 0
Study 11271178 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 545
Study 11271178 — intervention group
Group type: COMPARATOR
Intervention: CBIR
Number of subjects: 545
Study 3142635 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% noxythiolin
Number of subjects: 100
Study 3142635 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 100
Study 8174979 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg twice daily
Number of subjects: 25
Study 8174979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 102674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable fluoride tablets (1 mg of fluoride) once a day
Number of subjects: 0
Study 102674 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable fluoride tablets (1 mg of fluoride) twice a day
Number of subjects: 0
Study 102674 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet once a day
Number of subjects: 0
Study 31857570 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture group
Number of subjects: 189
Study 31857570 — intervention group
Group type: EXPERIMENTAL
Intervention: Common suture group
Number of subjects: 189
Study 31857570 — intervention group
Group type: COMPARATOR
Intervention: T‐tube drainage (TTD) group
Number of subjects: 189
Study 28257916 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music during UDS
Number of subjects: 148
Study 28257916 — intervention group
Group type: COMPARATOR
Intervention: No music during UDS
Number of subjects: 148
Study 24812035 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective stimulation
Number of subjects: 8
Study 24812035 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation
Number of subjects: 8
Study 24812035 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 8
Study 23463857 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN5A variant rs1805126
Number of subjects: 5272
Study 23463857 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN10A variant rs6795970
Number of subjects: 5272
Study 23463857 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN10A and SCN5A variants
Number of subjects: 5272
Study 23463857 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN10A variants
Number of subjects: 5272
Study 21291432 — intervention group
Group type: EXPERIMENTAL
Intervention: New Hope program
Number of subjects: 866
Study 21291432 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 866
Study 19013590 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 66
Study 19013590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 16895262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (6 g nightly for 4 weeks, then increased to 9 g nightly for 4 additional weeks)
Number of subjects: 270
Study 16895262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate plus modafinil
Number of subjects: 270
Study 16895262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 270
Study 16895262 — intervention group
Group type: COMPARATOR
Intervention: Modafinil (placebo)
Number of subjects: 270
Study 14718290 — intervention group
Group type: EXPERIMENTAL
Intervention: African American participants
Number of subjects: 439
Study 14718290 — intervention group
Group type: COMPARATOR
Intervention: Other participants
Number of subjects: 439
Study 11911512 — intervention group
Group type: EXPERIMENTAL
Intervention: One-point cane
Number of subjects: 30
Study 11911512 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-point cane
Number of subjects: 30
Study 11911512 — intervention group
Group type: COMPARATOR
Intervention: No cane
Number of subjects: 30
Study 9822507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (6 mg every 12 hours for a total of 4 doses)
Number of subjects: 24
Study 9822507 — intervention group
Group type: COMPARATOR
Intervention: Oral dexamethasone (8 mg every 12 hours for a total of 4 doses)
Number of subjects: 24
Study 9822507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 24
Study 8126916 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial infusions of epirubicin (Group B)
Number of subjects: 73
Study 8126916 — intervention group
Group type: COMPARATOR
Intervention: Intravenous epirubicin (Group C)
Number of subjects: 73
Study 8126916 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant therapy (Group A)
Number of subjects: 73
Study 8126916 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 73
Study 2536462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (mitomycin C 10 mg/m2, vinblastine 5 mg/m2, methotrexate 40 mg/m2, cisplatin 40 mg/m2 every 28 days)
Number of subjects: 105
Study 2536462 — intervention group
Group type: COMPARATOR
Intervention: Sequential single-agent chemotherapy (mitomycin C 10 mg/m2 monthly until progression, vinblastine 5 mg/m2 every 2 weeks until progression, methotrexate 40 mg/m2 weekly until relapse)
Number of subjects: 105
Study 4913786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prethcamide (200 mg, four times daily)
Number of subjects: 13
Study 4913786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prethcamide
Number of subjects: 13
Study 4913786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31177232 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music listening group intervention (60 minutes, 5 days/week for 8 weeks)
Number of subjects: 119
Study 31177232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 119
Study 28601264 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 128
Study 28601264 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 128
Study 25980660 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (50 L/min, FiO2 50%)
Number of subjects: 830
Study 25980660 — intervention group
Group type: COMPARATOR
Intervention: BiPAP (pressure support level 8 cm H2O, PEEP 4 cm H2O, FiO2 50%)
Number of subjects: 830
Study 25980660 — intervention group
Group type: COMPARATOR
Intervention: BiPAP
Number of subjects: 830
Study 25980660 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy
Number of subjects: 830
Study 23414742 — intervention group
Group type: EXPERIMENTAL
Intervention: High coronary artery calcium (CAC)
Number of subjects: 4074
Study 23414742 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobility limitation
Number of subjects: 4074
Study 23414742 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow gait
Number of subjects: 4074
Study 23414742 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint effect of high CAC and slow gait
Number of subjects: 4074
Study 20844886 — intervention group
Group type: EXPERIMENTAL
Intervention: Suturing (group A, n = 23)
Number of subjects: 45
Study 20844886 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocoagulation (group B, n = 22)
Number of subjects: 45
Study 18518888 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sweat gland suction curettage (SSGSC)
Number of subjects: 28
Study 16597081 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg once daily
Number of subjects: 1179
Study 16597081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1179
Study 12560306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% (L)
Number of subjects: 9
Study 12560306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5% plus sufentanil 0.75 microg (L+S)
Number of subjects: 9
Study 12560306 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 0.75 microg (S)
Number of subjects: 9
Study 12560306 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 9
Study 12560306 — intervention group
Group type: COMPARATOR
Intervention: Reference (REF)
Number of subjects: 9
Study 11487604 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 15
Study 11487604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9496344 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (1 mM)
Number of subjects: 138
Study 9496344 — intervention group
Group type: COMPARATOR
Intervention: Control (glucose-free medium without glutamine)
Number of subjects: 138
Study 7993600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese compounds and saliva due to masticating 20 gm hard cheese for 5 minutes
Number of subjects: 8
Study 7993600 — intervention group
Group type: COMPARATOR
Intervention: Stimulated saliva
Number of subjects: 8
Study 7993600 — intervention group
Group type: COMPARATOR
Intervention: Non-irradiated subjects
Number of subjects: 8
Study 2543596 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium cromoglycate (SCG) (7.3 +/- 0.6 mg)
Number of subjects: 11
Study 2543596 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium (NED) (7.5 +/- 0.6 mg)
Number of subjects: 11
Study 2543596 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SCG and NED
Number of subjects: 11
Study 17896753 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 14
Study 17896753 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 31530667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 731
Study 31530667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 731
Study 31530667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 731
Study 31530667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 731
Study 29544571 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous continuous infusion of tranexamic acid (TXA) at 5 mg/kg/hour
Number of subjects: 60
Study 29544571 — intervention group
Group type: COMPARATOR
Intervention: Three intravenous boluses of tranexamic acid (TXA) at 10 mg/kg after induction, after going to bypass and after protamine reversal
Number of subjects: 60
Study 26306891 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive test only
Number of subjects: 326
Study 26306891 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive test with specificity and sensitivity
Number of subjects: 326
Study 26306891 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive test with positive likelihood ratio in layman terms
Number of subjects: 326
Study 26306891 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall understanding of diagnostic accuracy parameters
Number of subjects: 326
Study 24785954 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplogroup B patients
Number of subjects: 118
Study 24785954 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplogroup B
Number of subjects: 118
Study 24785954 — intervention group
Group type: COMPARATOR
Intervention: Older age, higher baseline CD4 cell count, higher complex I level, and higher ENFD at baseline
Number of subjects: 118
Study 24785954 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐SN cases
Number of subjects: 118
Study 22528620 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMs from MedlinePlus
Number of subjects: 300
Study 22528620 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMs from EBSCO
Number of subjects: 300
Study 22528620 — intervention group
Group type: EXPERIMENTAL
Intervention: PEMs from Micromedex
Number of subjects: 300
Study 19157617 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance training using exercise bands
Number of subjects: 0
Study 19157617 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17186305 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedrest
Number of subjects: 10
Study 17186305 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study 15138837 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE gene insertion (I) allele
Number of subjects: 35
Study 15138837 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE gene deletion (D) allele
Number of subjects: 35
Study 15138837 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype frequencies (II versus ID versus DD)
Number of subjects: 35
Study 12474070 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml of red wine (12 % ethanol)
Number of subjects: 6
Study 12474070 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 % ethanol dilution
Number of subjects: 6
Study 12474070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine
Number of subjects: 6
Study 12474070 — intervention group
Group type: EXPERIMENTAL
Intervention: Red grape juice
Number of subjects: 6
Study 10434214 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellcor Symphony N‐3000 with Oxismart signal processing technique
Number of subjects: 603